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ABSTRACT
This article describes a good manufacturing practice (GMP)-compatible, feeder-free and serum-free
method toproduce largenumbers of erythroid cells fromhumanpluripotent stemcells (hPSCs), either
embryonic or induced. This multistep protocol combines cytokines and small molecules tomimic and
surpass the early stages of development. It produces, without any selection or sorting step, a popu-
lation of cells inwhich 91.8%6 5.4%express CD34 at day 7, 98.6%6 1.3%express CD43 at day 10, and
99.1%6 0.95% of cells are CD235a positive by day 31 of the differentiation process. Moreover, this
differentiation protocol supports extensive expansion, with a single hPSC producing up to 150 hema-
topoietic progenitor cells by day 10 and 50,000–200,000 erythroid cells by day 31. The erythroid cells
produced exhibit a definitive fetal hematopoietic type, with 90%–95% fetal globin and variable pro-
portion of embryonic and adult globin at the protein level. The presence of smallmolecules during the
differentiation protocol has quantitative and qualitative effects; it increases the proportion of adult
globin anddecreases theproportion of embryonic globin. Given its level of definition, this systempro-
vides a powerful tool for investigation of the mechanisms governing early hematopoiesis and eryth-
ropoiesis, including globin switching and enucleation. The early stages of the differentiation protocol
could also serve as a starting point for the production of endothelial cells and other hematopoietic
cells, or to investigate the production of long-term reconstituting hematopoietic stem cells from
hPSCs. STEM CELLS TRANSLATIONAL MEDICINE 2016;5:1–12
SIGNIFICANCE
This differentiation protocol allows the production of a large amount of erythroid cells from plurip-
otent stemcells. Its efficiency is compatiblewith thatof in vitro redblood cell production, and it canbe
a considerable asset for studying developmental erythropoiesis and red blood cell enucleation,
thereby aiding both basic and translational research. In addition to red cells, the early stages of
the protocol could also be used as a starting point for the large-scale production of other hemato-
poietic cell types, including the ultimate goal of generating long-term reconstituting hematopoietic
stem cells.
INTRODUCTION
Soon after the first derivation of human embryonic
stemcells (hESCs) [1], their capacity formultilineage
hematopoietic differentiation was demonstrated
[2] by using methods based on knowledge ac-
quired frommurine embryonic stem cells and de-
velopmental studies. More specific and defined
methods of differentiation were subsequently
developed but were mainly based on coculture
with somatic cell lines of various developmental
stages [3, 4], most commonly the OP9 murine
bone marrow stromal line. Other methods used
feeder-free (FF) methods based on the formation
of embryoid bodies (EBs) [5, 6]. Together these
methodsprovideda level of erythroid cell produc-
tion that allowed somedevelopmental studies [7]
and concurrently the idea that hESC-derived
erythrocytes might be used as an alternative to
donated red blood cells (RBCs) in transfusion
was emerging. However, these methods only
resulted in a small proportion of hESCs being con-
verted to hematopoietic cells [2–6], and the
small numbersof erythrocytes displayedpredom-
inantly embryonic/yolk sac characteristics [3–6].
As such, these early methods were qualitatively
and quantitatively insufficient for a putative ther-
apeutic use.
The production of RBCs from human pluripo-
tent stem cells (hPSCs) is the subject of growing
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interest because of the increasing global need for clinically safe
red blood cells (RBC) to meet transfusion requirements. More
efficient and defined methods are needed to progress basic
studies of erythropoiesis toward clinical translation either
by creating clinical-grade human feeders similar to those rou-
tinely used or by devising a completely FF/serum-free (SF) dif-
ferentiation method. The use of feeders, even xeno-free and
current good manufacturing practice (cGMP)-compliant ver-
sions, would be prohibitively costly and impractical for even-
tual large-scale production even if it were possible to generate
a line that recapitulates the effects of OP9 and other current
systems. However, an efficient FF/SF culture system would
offer a more practical solution, particularly in light of the
description of several small molecules that might be used to
address the issues.
The FF/SF erythroid differentiation of human pluripotent
stemcells grown inFF conditionshas longbeenhamperedbypoor
differentiation efficiency, low yield, primitive erythroid charac-
ter of the cells produced, and frailty of the cells obtained, such
that to date no fully FF/SF method has been published. The use
of feeders and serum not only hampers the development of pu-
tative cGMP protocols but also confounds the findings of basic
studies aiming to elucidate the complex biological mechanisms
involved in specification and differentiation. The most defined
differentiation systems published to date were those of Lu et al.
[8] in 2008 and Salvagiotto et al. [9] in 2011. However, in the first
study, the hESCswere grown on feeders and themethod proved
insufficient when they used induced pluripotent stem cells
(iPSCs) [10] instead of hESCs; in Salvagiotto and colleagues’
study, the functional erythroid differentiation was performed
in a methylcellulose assay, which doesn’t allow for complete
evaluation. Several additional studies have been reported,
but all used feeders [11] or serum/plasma [12] at some point,
whether their focus was to define biological aspects of erythro-
poiesis or to developmethods for the in vitro production of RBCs
for transfusion.
Here, we describe a highly efficient, fully FF/SF method for
erythroid differentiation of iPSCs and human embryonic stem
cells, including a clinical-grade line, that is amenable to scale-
up and as such will be of significant value for basic and transla-
tional studies of hematopoiesis and erythropoiesis.
MATERIALS AND METHODS
Cell Lines
Data are shown for thehESC linesRC9 (Roslin Cells Ltd, Edinburgh,
U.K., http://roslincells.com/), H1, and H9 (WiCell, Madison, WI,
http://www.wicell.org/), and an iPSC line, 33D6 [13]. In addition,
we tested six newly derived iPSC lines from blood group O RhD2
donor fibroblasts (University of Edinburgh, Edinburgh, U.K.), five
iPSC lines derived fromperipheral blood [14], and five other hESC
lines, including RC11 (Roslin Cells), all of which differentiated suc-
cessfully in this protocol. Both RC lines were derived and banked
at clinical grade.
Undifferentiated hPSCsweremaintained in Stempromedium
(Thermo Fisher Scientific Life Sciences, Waltham, MA, http://
www.thermofisher.com) supplemented with 20 ng/ml of basic
fibroblast growth factor (FGF) (FGF2; R&D Systems, Abingdon,
U.K., https://www.rndsystems.com) on recombinant vitronectin
(Thermo Fisher Scientific Life Sciences) and mechanically passaged
approximately every 7 days, depending on their level of conflu-
ence, using the EZPassage tool (Thermo Fisher Scientific Life
Sciences).
For differentiation, hPSC cultures, at 80%–100% confluence,
were cut into squares with the EZPassage tool and plated at
200 3 103 to 600 3 103/well in ultra-low-adherence six-well
plates (Corning, Corning, NY, https://www.corning.com/) in
3ml of Stemline IImediumperwell (Sigma-Aldrich, Gillingham,
U.K., https://www.sigmaaldrich.com/) to form EBs.
On day 0, to induce differentiation, the following cytokines
(Mix A1) were added: bone morphogenic protein 4 (BMP4)
(10 ng/ml) (R&D Systems), Vascular endothelial growth factor
165 (VEGF) (10 ng/ml) Activin A (5 ng/ml) (both from PeproTech
EC Ltd., London, U.K., https://www.peprotech.com/), Wnt3A
(10 ng/ml) (R&D Systems), and GSK3b inhibitor VIII (2 mM) (N-[4-
methoxybenzyl]-Nʹ-[5-nitro-1,3-thiazol-2-yl] urea) or A-A014418
(Calbiochem; Millipore [UK] Ltd., Feltham, U.K., http://www.
emdmillipore.com/).
On day 2 of differentiation (EBs 48 hours old), a new set of
cytokines (Mix A2) was added to the existing culture volume in
0.5 ml of Stemline II per well. Cytokines were added at 36 con-
centration to supplement the entire volume such that the final
concentrations in the well (assumed volume, 3 ml) were BMP4
(20 ng/ml), VEGF (30 ng/ml), Wnt3A (10 ng/ml), Activin A (5 ng/ml),
inhibitor VIII (2mM), acidic FGF (FGFa) (10 ng/ml) (FGF1; PeproTech),
stem cell factor (SCF) (20 ng/ml) (Thermo Fisher Scientific Life Sci-
ences), and b-estradiol (0.4 ng/ml) (Sigma-Aldrich).
Onday3ofdifferentiation, theEBswereharvested,washed in
phosphate-buffered saline (PBS), then dissociated using TrypLE-
Select310 (Thermo Fisher Scientific Life Sciences) for 10minutes
at 37°C. After addition of PBS and centrifugation, the cells were
resuspended in fresh Stemline II and plated at 200 3 103/well
of a standard six-well tissue culture plate with the following fac-
tors (Mix B): BMP4 (20 ng/ml), VEGF (30 ng/ml), FGFa (10 ng/ml),
SCF (30 ng/ml), insulin-like growth factor (IGF) 2 (10 ng/ml),
thrombopoietin (10 ng/ml) (PeproTech), heparin (5 mg/ml), iso-
butyl methyl xanthine (IBMX) 50mM (Sigma-Aldrich) and b-estradiol
(0.4 ng/ml).
On day 5 of differentiation, the differentiation factor Mix B
was refreshed by adding 0.5 ml Stemline II per well with36 con-
centration of cytokines and the small molecule StemRegenin
(SR1) (Cellagen Technology, San Diego, CA, http://www.
cellagentech.com/) is added to give a final concentration of
1 mM in the culture medium.
On day 7 of differentiation, the cells underwent a complete
medium change and were put back into Stemline II medium sup-
plemented with the Mix B factors. If the number of cells was
greater than 5003 103/ml, the culture was split and the density
reset to 200 3 103/ml to support proliferation.
Fromdays 7 to 10 of differentiation, the cell density had to be
closely monitored and the cell number was maintained below
106 per ml by adding fully supplemented media and splitting into
additional wells as required.
On day 9 of differentiation, a half-dose ofMix B cytokineswas
added in 0.5 ml of Stemline II per well.
On day 10 of differentiation, after centrifugation, the cells
were replated in erythroid liquid culture conditions. That is, the
cells were plated at a density of 100 3 103 cells/well in 3 ml of
Stemline II per well supplemented with the following factors
(Mix C): hydrocortisone 1 mM, SCF (50 ng/ml) (Sigma-Aldrich),
Flt3-ligand (16.7 ng/ml) (PeproTech), BMP4 (6.7 ng/ml),
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interleukin (IL) 3 (6.7 ng/ml) (PeproTech), IL11 (6.7 ng/ml) (Pepro-
Tech), IBMX (50 mM), and erythropoietin (EPO) (NeoRecormon,
Roche Products Ltd., Welwyn Garden City, U.K., http://www.
roche.com) 1.3U/ml. Fromdays 10 to 17, the preceding cytokines
and factors were refreshed every 2 days by adding 36 Mix C in
0.5 ml of Stemline II.
On days 14 and 16, Pluripotin (SC1) (Stemgent, Reinnervate
Ltd., Sedgefield, U.K., http://reinnervate.com/) is also added at
a final concentration of 500 nM in the culture medium.
On day 17 of differentiation the cells were centrifuged for
3 minutes at 300g, then replated at a density of 0.5–1 3 106
cells/well in 3ml of IBITmediumperwell (composedof incomplete
Iscove’s medium with stable glutamine (Biochrom AG, Millipore
Ltd.), 1% bovine serum albumin (BSA; BioXtra; Sigma-Aldrich),
10 mg/ml insulin and 200 mg/ml holo-transferrin (both from
Sigma-Aldrich), and xeno-free lipid mixture solution (supplied as
3200; Sigma-Aldrich) supplemented with the following factors
and cytokines (Mix D): hydrocortisone (1 mM), SCF (20 ng/ml), IGF
1 (20 ng/ml) (PeproTech), IL3 (6.7 ng/ml), IL11 (6.7 ng/ml), and
EPO 2 U/ml. The BSA in the IBIT could be replaced by human serum
albumin (1% final vol/vol) for a xeno-free version of the medium.
From days 17 to 24, the medium was refreshed with Mix D
every 2 days, added at36 concentration in 0.5ml of IBITmedium
per well, as noted earlier.
On day 24 of differentiation, the cells were replated at a den-
sity of 0.5–13 106/ml in IBIT supplemented with 4 U/ml EPO for
2 days, followed by 5–10 days in IBIT medium alone. The culture
medium was refreshed every 2 days by addition of IBIT medium.
Analysis and Characterization
Atdays 0, 3, 5, 7, and10, cellswere analyzedby flowcytometry for
expression of SSEA3, SSEA4, and TRA1-60 (BD Biosciences, Ox-
ford, U.K., http://www.bdbiosciences.com/; R&D Systems; and
eBioscience Ltd., Hatfield, U.K., http://www.ebioscience.com/)
to track the loss of pluripotency of the hPSCs during the differen-
tiation process.
During differentiation, cells were analyzed by flow cytometry
toevaluate theirhematopoietic anderythroid characteristics. The
antibodies usedwere directed against CD31, CD34, CD36, CD41a,
CD43, CD44, CD45, CD71, and CD235a (BD Biosciences and eBio-
science), and the cells were analyzed with a BD FACSCalibur or
CantoII flow cytometer (BD Biosciences).
At day 17 onward, the erythroid stage of the cells was also de-
termined by assessment ofmorphology after Rapid Romanowsky
staining of cytospin preparations (TAAB Laboratories Equipment
Ltd., Aldermaston, U.K., http://www.taab.co.uk/). Slides were
assessed by light microscopy using a Zeiss Axio microscope and
an Axio Cam MRc camera (Zeiss, Cambridge, U.K., http://www.
zeiss.com/).
At days 0, 10, 17, and 24, the expression of selected genes of
interest in the differentiating cells wasmonitored by quantitative
real-time polymerase chain reaction (Taqman 7900; Thermo Fisher
Scientific Life Sciences) using a custom low-density array card. The
gene panel was selected to comprise genes known to be expressed
at various stages of hematopoiesis and erythropoiesis to evaluate
the degree of differentiation of the hPSCs.
High-Performance Liquid Chromatography
Atday 24or onward, the globinwas analyzed by high-performance
liquid chromatography (HPLC) to determine the nature and the
proportion of the chains expressed at the protein level. The ery-
throid cells werewashed 3 times in PBS and lysed inwater through
3 cycles of freezing/thawing. The cells were then centrifuged at
13,000 g at 4°C for 10 minutes and the supernatant collected for
HPLC analysis. Globin chain separation was performed by injecting
10 ml of the supernatant onto a 1.0 3 250-mm C4 column (Phe-
nomenex, Macclesfield, U.K., http://www.phenomenex.com/)
with a 42%–56% linear gradient between mixtures of 0.1% tri-
fluoroacetic acid (TFA) in water (Buffer A) and 0.1% TFA in ace-
tonitrile (Buffer B) at flow rate of 0.05 ml/min for 55 minutes on
an HPLC Ultimate 3000 system (Dionex, Thermo Fisher Scientific
Life Sciences). The column temperature was fixed at 50°C during
analysis and the ultraviolet detector was set at 220 nm. Lysates
from adult peripheral blood and fetal liver were used as refer-
ence controls. Elution times of peaks generated were compared
with that of the control peaks for identification. Percentage of
total globin was calculated for each chain using the area under
the curve function in the Dionex Cromeleon Chromatography
Data System.
RESULTS
To improve theyield andmaturity of hPSC-derived erythroid cells,
wehavedevelopedamultistep, cGMP-compatible differentiation
protocol that combines cytokines and small molecules to mimic
the early stages of development while enhancing the intermedi-
ate populations. We have successfully used this method onmore
than 10 different hPSC lines that had also been grown in FF/SF
conditions before differentiation.
Themethod comprises fivemajor steps, illustrated in Figure 1
anddetailed in theMaterials andMethods section. The smallmol-
ecules were tested at various stages of the differentiation proto-
col for various lengthsof timeandwere found tobemosteffective
in inducing maximum amplification when added to culture me-
dium following the timing indicated.
The undifferentiated hPSC colonies were initially allowed to
form EBs after being mechanically cut, which minimized the size
of the EBs, in order to optimize exposure to the cytokine and
small molecule mix A1 that was added on day 0 of the differen-
tiation. On the second day of differentiation (48-hour EBs), the
cytokines and GSK3b inhibitor VIII are renewed (Mix A2) with an
increase of BMP4 and VEGF concentration plus the introduction
of FGFa, SCF, and b-estradiol to enforce the differentiation to-
wardmesodermwhile priming for the hemato-endothelial com-
partment [15–17].
Because canonical Wnt signaling triggered by Wnt3A has
been reported to bemimicked byGSK3b inhibitors [18] that pre-
vent phosphorylation of b catenin, causing its release from the
axin complex, we tested whether small molecule GSK3b in-
hibitors could be used instead of cytokines to deliver a more
potent signal at a lower cost.We initially tested BIO (29Z,39E)-
6-bromo-indirubin-39-oxime), the first archetypal GSK3b in-
hibitor, with poor results, likely because of the wide range of
off-target kinases it inhibits (supplemental online Table 1).
When we replaced BIOwith inhibitor VIII, a highly specific GSK3b
inhibitor, we observed that it was not only an apparent replace-
ment for Wnt3A but when used in combination it increased the
Wnt effect and improved the quality of the cells produced later
in the differentiation process. This was demonstrated by the
persistence of intact cells after day 24 in contrast to cultures
lacking inhibitor VIII where cell numbers fell as the cells become
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fragile and broke up (supplemental online Fig. 4). Subsequently,
we found that GSK3b inhibitor CHIR99021 could be used in
place of inhibitor VIII; however, the concentration had to be
closely controlled because this more potent agent could favor
the formation of mesenchymal stem/stroma cells over the
hemato-endothelial compartment in our protocol (data not
shown).
As shown in Figure 2A the addition of inhibitor VIII alone
could have a significant effect on the overall yield of cells
produced, but this effect varied depending on the hPSC line
used (supplemental online Fig. 1A and 1B, left panels). The
main effect of inhibitor VIII, when used alone or with Wnt3A,
was the qualitative improvement observed in the late-stage
cells.
On the thirddayofdifferentiation, theEBswereenzymatically
dissociated and the cells were plated at lowdensity in fresh Stem-
line II with Mix B, including IBMX.
IBMX is a nonspecific inhibitor of cAMP and cGMPphospho-
diesterases that is commonly used to increase the pool of
intracellular cAMP [19] and to reduce the effect of tumor necro-
sis factor (TNF) a. The role of cAMP in HSC specification has re-
cently been reported by Diaz et al. [20], and increased cAMP has
been shown to drive erythroid proliferation [21]. TNFa is a rec-
ognized inhibitor of hematopoietic progenitor development
and of erythropoiesis [22]. Therefore, we tested whether IBMX
could improve the yield and quality of cells generated during dif-
ferentiation. As shown in Figure 2A (and supplemental online
Fig. 3), IBMX significantly increased the number of cells pro-
duced per differentiating hPSC without any effect on the cell
phenotype.
MixBwas renewedevery2dayswith the inclusionof 1mMSR1
onday 5where required. A completemediumchange on day7was
done to remove debris and dead cells, as well as to provide suffi-
cient nutrients for the proliferative burst that occurs from days 7
to 10. At this point, the cell density had to be closely monitored
to prevent the loss of hematopoietic potential and proliferation.
The cytokine formulationused fromdays3 to10wasbasedon
our previous work and that of others [23–25]. It was intended to
Figure 1. Diagram representing the feeder-free and serum-free erythroid differentiation of hPSCs augmented by the addition of small mol-
ecules. Abbreviations: BMP, bone morphogenic protein; EBs, embryoid bodies; EPO, erythropoietin; FGF, fibroblast growth factor; Flt3L,
Flt3-ligand; hPSC, human pluripotent stem cells; HSPCs, hematopoietic stem and progenitor cells; IBIT, IMDM + bovine serum albumin,
insulin, transferrin; IBMX, isobutyl methyl xanthine; IGF, insulin-like growth factor; IL, interleukin; RBCs, red blood cells; SCF, stem cell factor;
TPO, thrombopoietin; VEGF, vascular endothelial growth factor 165.
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favor and maintain the formation and amplification of the
multipotent hematopoietic progenitor cells (HPCs), as shown in
the marker profile and gene expression (Fig. 3; supplemental
online Fig. 2). Moreover, the quantitative polymerase chain reac-
tion analyses (Fig. 2B) demonstrated a positive effect of the inclu-
sion of inhibitor VIII and IBMX on the expression of a set of
key hematopoietic mRNAs. GATA1 and 2, RUNX1, BMI1, GFI1B,
LMO2 and 4, MYB, RAF1, MYC, and TAL1 (SCL) were chosen as
transcription factors with an established role in hematopoietic
stem cells and/or erythroid lineage commitment and which we
expected tobe expressedwithin this specific time frame. The long
noncoding RNAMALAT1was added to the panel because it shows
an interesting correlation of expressionwith somegenes involved
in erythroid differentiation [26]. The addition of inhibitor VIII and
IBMX significantly increased the relative expression of all of these
genes at day 10 with the exception of GFI1B, consistent with ex-
pression data showing its expression increasing at the later
megakaryocyte-erythroid progenitor stage [26].
In light of previous reports that antagonists of the aryl hy-
drocarbon receptor (AhR) increase proliferation of HPC [27], we
added SR1 to extend theperiodoverwhich CD34-positive hema-
topoietic cells emerged. HPCs are characterized in part by ex-
pression of the CD34 antigen and the maximum proportion of
cells expressing CD34+ was observed at day 7, as shown in
Figure 3, where CD34 can be detected on 91.8%6 5.4% of cells
analyzed.
Further confirmation of hematopoietic identity is provided by
analysis of the CD43 antigen [28]; at day 10, flow cytometry
Figure 2. Analysis of the quantitative effects of the small molecules used on erythroid differentiation of H1 embryonic stem cells (ESCs). (A):
Additional use of small molecules increased the yield of erythroid cells. Histograms representative of the small molecule effect on the yield of
erythroid cells from theH1 hESC line, expressed as percentage of total amplification relative to the control. Left panel, effect of inhibitor VIII and
IBMX assessed at day 24 of the differentiation. n = 3;mean6 SD. Unpaired t test; p, p, .05. Right panel, effect of SR1 and SR1 + SC1 assessed on
day 31 of the differentiation, when used in addition of Inhibitor VIII and IBMX. n $ 4; mean6 SD. Unpaired t test; p, p, .05, pp, p, .01. (B):
Inhibitor VIII and IBMXaddition increase the transcription of key genes involved in hematopoiesis. Quantitative polymerase chain reaction anal-
ysis of the effect of inhibitor VIII and IBMX at day 10 of the differentiation on genes known to be expressed during hematopoietic and erythroid
development. n = 4 performed in duplicate; mean6 SD. Unpaired t test; p, p, .05; pp, p, .01; ppp, p, .001. Abbreviations: IBMX, isobutyl
methyl xanthine; ns, not significantly different.
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analysis showed that 98.6%6 1.3% of cells expressed this impor-
tant marker (Fig. 3; supplemental online Fig. 2A). From the panel
of antigens detected on the cells from days 7 to 10, and notably
the simultaneous presence of CD31, CD34, CD41a, CD43, and
CD235a, it appears that most cells were at the hemangioblastic
or posthemangioblastic stage [5]. Between days 7 and 10, when
using regular, adherent cell culture plastics, we observed a great
proliferation of cells budding from aweb of loosely attached cells
(supplemental online Fig. 6), which could be likened to a hemo-
genic endothelium [29]. This was consistent with the expression
Figure 3. Analysis of the qualitative effects of the small molecules used on erythroid differentiation of H1 embryonic stem cells (ESCs). Addition of
smallmoleculesdoesnotmodify thesurfacemarkerprofileofdifferentiating cells. Antigenicprofileof thecultureduring theerythroiddifferentiationof
H1 human ESCswith (red lines) orwithout (Control; blue lines) smallmolecules (+SM; inhibitor VIII + IBMX+ SR1 + SC1). The pluripotentmarkers show
the lossofpluripotencyduring the first5days.TheHPCmarkers showtheemergenceof thehematopoietic cellswithapeakofhemangioblasticmarkers
CD34, CD31, and CD41a at day 7. The erythroid cell markers CD36 (denoting the commitment toward erythroid lineage) and CD235a (also known as
glycophorin A) confirm the evolution of the culture toward an almost pure erythroid population between days 17 and 31. Abbreviations: HPC, hema-
topoietic progenitor cell; SM, small molecules. An example of individual flow cytometry plots is shown in supplemental online Fig. 7.
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of themarkersobservedat the cell surface, and further cultivation
of the attached cell fraction in appropriate conditions resulted
in the generation of CD144+/CD31+ endothelial cells (data not
shown). However, we also achieved similar expansion and ery-
throid differentiation when the cells were maintained in nonad-
herent plastic from day 3 to day 10 (data not shown); this would
be important for scale-up as the entire protocol canbeperformed
in suspension for example in bags or stirred tank reactors.
Fromdays 10 to 17, the cells were placed in erythroid-specific
liquid culture starting from low-seeding density. The small mole-
cule SC1 [30], a dual RasGAPand ERK1/2 inhibitor, was addedon
days 14 and 16 to enhance the multiplication of the erythroid
progenitors by slowing down progression toward a more ma-
ture phenotype. This resulted in the longer persistence of the
CD43 and CD44 [31, 32] markers (Fig. 3; supplemental online
Figs. 2A and 5B) and a higher yield of erythroid cells (Fig. 2A;
Figure 4. Erythroid cellmorphology progresses over time in thedifferentiating cultures and in the late stages is substantially improvedby theadditionof
different combinations of SMs as labeled. Photographs of rapid Romanowsky staining of cytospin preparations at different stages of the differentiation
that show theeffects of different combinationof smallmoleculeson themorphologyof thedifferentiating anddifferentiated cells at days17, 24, and31of
the protocol. Originalmagnification3400; scale bars = 10mm. For reference, images of themorphologically distinct stages of erythroid differentiation are
within Figures 4 and 5 of Hu et al. [44]. Abbreviations: DMSO, dimethyl sulfoxide; IBMX, isobutyl methyl xanthine; SM, small molecules.
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supplemental online Figs. 1 and 5A). The addition of these small
molecules did not otherwise modify the antigenic profile of the
differentiating cells (Fig. 3).
At day 17, the antigen expression profile, as well as rapid
Romanowsky staining of cytospins, showed that most cells were
of the erythroid lineage, with most of them pro- or basophilic
normoblasts (Figs. 3 and 4). At this stage, the basal medium
was switched to IBIT because Stemline II did not support fur-
ther erythroblast maturation. The corresponding cytokine
cocktail Mix D of hydrocortisone, SCF, IGF1, IL3, IL11, and
EPO was refined [24] to produce cells that display the highest
levels of erythrocytic markers and was again refreshed every
2 days.
At day 24 of the differentiation, most cells were erythroid,
as shown by the flow cytometry analysis, with expression of
CD235a on 84.8% 6 8.7% of the cells and CD36 on 85.3% 6
3.3% of the cells (Fig. 3; supplemental online Fig. 2A). Impor-
tantly, no sorting or other purification step was required to
achieve these predominantly erythroid cultures. The corre-
sponding cytospins show a variable distribution among the ba-
sophilic, polychromatic, and orthochromatic subclasses of
erythroblasts, depending on the differentiation condition
tested and the origin of the hPSCs used (Fig. 4). From this point,
whenmaintained in IBIT supplemented with EPO for 2 days, fol-
lowed by 5–10 days in IBIT medium alone, the differentiating
cells evolved toward an almost homogenous population of or-
thochromatic normoblasts with 99.1% 6 0.95% expressing
CD235a and up to 10% of cells undergoing spontaneous enucle-
ation (Fig. 4). Despite a longer period of amplification, the cells
treated with all 4 small molecules also exhibited more mature
morphology at day31,withmoreenucleated cells visible. In con-
trast, cells that had not received inhibitor VIII and IBMX rapidly
died off and fragmented in culture after day 24, demonstrating
the relative fragility of cells grown under those conditions
(supplemental online Fig. 4).
Having tested the small molecule and cytokine mixes individ-
ually and together to assess the extent of their effect (exemplified
in supplemental online Fig. 5), the cumulative effect of the factors
tested support the production of up to 200,000 erythroid cells
from a single hPSC (Fig. 5) over 31 days. As such, a full transfusion
unit of 2 3 1012 cells could be generated from just 10 million
hPSCs, which can easily be harvested from a single 6-well plate
or T75 flask.
Furthermore, at day 31, HPLC analysis of globin chain expres-
sion confirmed the definitive character of the cells produced [7]
(Fig. 6B). Fetal globin chains (a and g) predominatedwith low, re-
sidual expression of embryonic globin (« and z chains) and a small
amount of the adult b globin chain at the protein level. The small
molecules used decreased the proportion of embryonic globin
(« chain, 11.3% 6 2.4% with dimethyl sulfoxide [DMSO] alone
vs. 3.1% 6 1.1%, with small molecules, and z chain 5.4% 6
0.8% vs. 1.8% 6 0.3%) and increased the proportion of adult
b-globin chain (3.4% 6 0.4% vs. 2.2% 6 0.6%) (Fig. 6A and 6B;
supplemental online Figs. 2B and 5C; mean values from H1 and
H9 lines). The expression ofmore developmentallymature globin
in response to the addition of the small molecules may be due to
increased survival or amplification of definitive progenitors over
the precursors that produce erythroid cells with embryonic glo-
bin. This predominantly fetal globin expression is compatiblewith
transfusion use and is similar to umbilical cord blood; the detec-
tion of b-globin protein indicates that the locus is not fully
silenced, and so switching to adult globin might be achieved in
these cells with additional stimuli.
DISCUSSION
Methods of differentiation that rely on feeder cells and/or serum
introduce uncontrolled variables that may confound the find-
ings of mechanistic studies, particularly those investigating
the effect of growth factors and cytokines on hPSC differenti-
ation. There are still challenges that translate on a practical
level into difficulty in switching from complex commercial me-
dium (e.g., Stemline II) to completely chemically defined con-
ditions (e.g., APEL medium [33] or using recombinant human
serum albumin) while maintaining similar efficiency. Nonethe-
less, more highly defined culture conditions advance progress
toward the goal to translate basic science into biotechnology
and clinical utility, and many applications could benefit from
an improved method for the hematopoietic differentiation of
hPSCs. Among the most obvious is the capability to provide
large amounts of reproducible material, which will allow more
precise investigation of themechanisms governing hematopoi-
esis, including globin switching and enucleation during eryth-
ropoiesis, by enabling multiomics and functional studies or
pharmacological screening. The use of liquid culture conditions
simplifies the testing of soluble factors as well as the scale up
into bioreactors.
This method also forms the basis of a cGMP-compatible sys-
temthat could be scaledup toderive sufficient cells for in vivo and
first-in-human studies of cultured red blood cells once efficient
enucleation is attained.
The use of small molecules has expanded from mechanistic
signaling studies to use for reprogramming of somatic cells and
maintenance of PSCs [30, 34]. More recently they have increas-
ingly been used in methods to differentiate hPSCs in various cell
types from all germ layers [35]. Several methods using small mol-
ecules for the endothelial differentiation of hPSCs have already
been published [36, 37], in which the use of GSK3b inhibitors
resulted in enhanced induction ofmesodermal lineages as similar
Figure 5. Illustration of the yield achieved with different cell lines.
Fold amplification of the initial input of human pluripotent stem
cells (hPSCs) to the erythroid stage obtained with four different
hPSC lines: RC9, n = 5; H1, n = 4; H9, n = 3; iPSC 33D6, n = 5. Abbre-
viation: iPSC, induced pluripotent stem cell.
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Figure 6. High-performance liquid chromatography (HPLC) analysis of the globin chains expressed at day 31 of H1 human embryonic stem cell
(hESC) differentiation. (A): Example of elution profiles obtained byHPLC of H1 hESC-derived erythroid cells with (SM) andwithout (DMSO) small
molecules andof the adult and fetal control used to determine theelution timeof the different globin chains. (B):Globin chainswere assessed at
(Figure legend continues on next page.)
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to that reported here. Also, the recent publication of Patsch et al.
[38] described an endothelial differentiationmethod, very similar
to the one of Sahara et al. [36], using forskolin to activate adenyl
cyclase and resulting in increased intracellular cAMP and en-
hanced differentiation.
The use of small molecule effectors specifically to promote
erythroid differentiation of hPSCs has not been reported previ-
ously, although activin inhibitors such as SB 431542 have been
used at early time points to try to enhance the production of
a more definitive hematopoietic stem and progenitor cell
and thereby alter the balance of primitive (embryonic globin
expressing) and definitive (fetal/adult globin-expressing) ery-
throid cells [39]. Similarly, Smith et al. [40] reported that aryl
hydrocarbon receptor activation with 6-formylindolo[3,2-b]
carbazole (FICZ) increased HPC with the capacity to undergo
erythroid and megakaryocytic differentiation. Somewhat sur-
prisingly, we saw long-lasting effects of small molecule use
such that exposure to GSK3b inhibitors between days 0 and
3, transient use of SR1 at day 5, and SC1 at days 14–16 have
strong effects on the quality of the cells produced up to 2–3
weeks later.
Before the introduction of these smallmolecules in the differ-
entiation process, we observed a strong decline of the erythroid
culture after day 24, consistent with the observation of Feng
et al. [10] that terminal differentiation of hPSC-derived ery-
throid cells is impaired, leading to cell death. This method still
uses EBs and is not yet compatible with two-dimensional mono-
layer induction; however, comparedwith themonolayer system
reported by Salvagiotto et al. [9], we generated up to 150 times
the number of CD43+ cells over 10 days instead of 14 days. The
most similar published method with regard to cell yield was re-
ported by Dias et al. [11]. However, thatmethod used xenogenic
feeder cells and took more than 65 days to reach a similar stage
of maturation.
Perhaps the most remarkable property of the differentiation
system reported here is the relative purity of erythroid cell pro-
duction in the absence of any sorting or selection steps. The
cytokine/smallmolecule combinations are sufficient to induceex-
tensive hematopoietic, and subsequently erythroid, differentia-
tion and expansion while not supporting other lineages. The
few (,5%) nonerythroid cells that are observed at late time
points are monocytic in morphology and phenotype. Therefore,
we believe that this protocol surpasses previously published
methods with respect to the level of definition of the compo-
nents, the yield of erythroid cells obtained and the time period
during which this was achieved.
As with other published methods, the level of enucleation is
limited; however, if the total yield of cells is used along with the
percentage enucleation to calculate the absolute number of enu-
cleated cells generated per hPSC, this method produces a higher
total number of reticulocytes than methods with higher percent-
age enucleation butmuch lower cell expansion. The recent report
of Rouzbeh et al. [41] demonstrated that it might be possible to
increase thepercentageof cells undergoing enucleationby reduc-
ing the expression of micro RNA30a (MIR30a); however, there
was very little, if any, cell expansion in their system. Furthermore,
knockdown of an MIR is a difficult strategy to use routinely,
whereas identification of the MIR30a targets and development
of small molecules effectors would increase the utility of the
method and could be easily tested in the high-yield, highly de-
fined differentiation system reported here.
This studyhighlights several interesting leads for future inves-
tigation. We observed an additive activity of Wnt3A signaling
and GSK3b inhibitors, which could be due to the role of nonca-
nonicalWnt signaling or additional action of GSK3b, such as the
maintenance of DNA methylation [42], but shows that it would
be erroneous to assume that a small molecule GSK3b inhibitor
can simply replace a bioactive Wnt glycoprotein without full
analysis of downstream effects. The timing and duration of
small molecule supplementation were essential; for example,
we found that the use of SC1 (Pluripotin) during the first week
of differentiation, or for a more prolonged period, had a nega-
tive effect on cell proliferation, although by analogy to its re-
ported effects on PSCs [30], it might have been expected to
have maximal beneficial effect at early time points on the first
arising hematopoietic progenitors.
We also found that the published phenotypic action of some
small molecules may be dependent on the combination of all
the factors involved. For example, we did not observe any ef-
fect when using the AhR agonist FICZ [40] or with stauprimide
[43] in our method. This may because the target pathways are
active only in a more primitive differentiation stage (in the
case of FICZ) or becausewe had already stimulated these path-
ways with other components of our system as we observed
lower levels of apoptosis and higher erythroid specification
and expansion in the absence of FICZ than those reported by
Smith et al. [40] when it was added. We are performing
detailed analyses to determine the molecular mechanisms
underlying the high efficiency generation of erythroid cells
that we report here.
CONCLUSION
The combination of cytokines and small molecules in a feeder-
free, serum-free protocol has proven to be an effective solution
to most of the issues that have hampered researchers trying to
produce large numbers of erythroid cells from hPSCs. This proto-
col results in high differentiation efficiency, high yield, and the
generation of robust cells that have definitive erythroid charac-
teristics, as demonstrated by the predominant expression of
nonembryonic globin. These cells can readily be used in studies
tomodelnormalordiseasederythropoiesis, and the largecell num-
bers achievable would allow extensive analysis, including multio-
mics, metabolic, and chromatin-protein interaction assays (such
as chromatin immunoprecipitation [ChIPorChIP sequencing]) over
sequential time points from the same culture. We have demon-
strated this potential by using the method to differentiate iPSC
from normal donors and those with pyruvate kinase deficiency
(PKD) before and after gene correction, and we were able to
(Figure legend continued from previous page.)
theprotein level after erythroiddifferentiationwith (SM)orwithout (DMSO) the4 smallmoleculesadded (inhibitorVIII + isobutylmethyl xanthine+
SR1 + SC1). Lysates from adult peripheral blood and fetal liver red blood cells were used as reference controls to establish the elution time of each
peak. Abbreviations: DMSO, dimethyl sulfoxide; SM, small molecules.
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determine the effect of gene correction in erythroid cells differen-
tiated from PKD-iPSCs [14].
Given the level of definition, robustness, simplicity, and ab-
sence of genetic modification, the differentiation method pre-
sented here also offers a versatile tool to study most aspects
of hPSC-derived hematopoiesis. Notably, it could be a stepping
stone in the quest to produce transplantable, long-term reconsti-
tuting hematopoietic stem cells from hPSCs thatmight be used in
the future to replace donated stem cells and/or combined with
genome engineering technologies to correct disease-causing
mutations.
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